Autolus Therapeutics’ (AUTL) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTLFree Report) in a research report released on Monday, Benzinga reports. They currently have a $9.00 price target on the stock.

AUTL has been the topic of several other reports. Truist Financial lifted their price target on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a buy rating in a report on Tuesday, April 9th. William Blair reaffirmed an outperform rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $8.70.

View Our Latest Analysis on AUTL

Autolus Therapeutics Stock Down 1.0 %

Shares of NASDAQ:AUTL opened at $3.86 on Monday. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -3.22 and a beta of 2.02. Autolus Therapeutics has a 52 week low of $2.01 and a 52 week high of $7.45. The firm has a 50 day moving average of $4.19 and a 200 day moving average of $5.34.

Autolus Therapeutics (NASDAQ:AUTLGet Free Report) last released its quarterly earnings results on Friday, May 17th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The business had revenue of $10.09 million for the quarter, compared to analyst estimates of $50.00 million. During the same quarter in the prior year, the company earned ($0.23) earnings per share. On average, sell-side analysts expect that Autolus Therapeutics will post -0.78 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of large investors have recently made changes to their positions in AUTL. Bayesian Capital Management LP purchased a new stake in shares of Autolus Therapeutics during the first quarter valued at $100,000. China Universal Asset Management Co. Ltd. acquired a new position in Autolus Therapeutics during the fourth quarter valued at $105,000. B. Riley Wealth Advisors Inc. acquired a new position in Autolus Therapeutics during the first quarter valued at $108,000. SG Americas Securities LLC acquired a new position in Autolus Therapeutics during the first quarter valued at $127,000. Finally, EntryPoint Capital LLC lifted its position in Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after purchasing an additional 11,456 shares during the period. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Recommended Stories

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.